
FDA clears DeFloria’s cannabis-based autism treatment for phase 2 trial
DeFloria said Monday that the Federal Drug Administration has stamped the firm’s application to begin a Phase 2 clinical trial for AJA001, an oral cannabinoid drug being made to treat symptoms of autism spectrum disorder. The company, which was formed in …